Jose Luis Calleja
Overview
Explore the profile of Jose Luis Calleja including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
2945
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rivera-Esteban J, de la Iglesia Garcia D, Agudo-Castillo B, Calleja J, Llop E
Endoscopy
. 2025 Feb;
57(3):295.
PMID: 40010318
No abstract available.
2.
Marti-Aguado D, Calleja J, Bataller R, Crespo J, Arias-Loste M
J Hepatol
. 2025 Feb;
PMID: 39914745
No abstract available.
3.
Yip T, Lee H, Lin H, Tsochatzis E, Petta S, Bugianesi E, et al.
J Hepatol
. 2025 Jan;
PMID: 39863175
Background & Aims: Current guidelines recommend a 2-step approach for risk stratification in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) with Fibrosis-4 index (FIB-4) followed by liver stiffness measurement...
4.
Sanchez-Aldehuelo R, Villanueva C, Genesca J, Garcia-Pagan J, Castillo E, Calleja J, et al.
JHEP Rep
. 2025 Jan;
7(2):101231.
PMID: 39850960
Background & Aims: Systemic inflammation is a driver of decompensation in cirrhosis with unclear relevance in the compensated stage. We evaluated inflammation and bacterial translocation markers in compensated cirrhosis and...
5.
Fortea J, Alvarado-Tapias E, Simbrunner B, Ezcurra I, Hernandez-Gea V, Aracil C, et al.
J Hepatol
. 2024 Dec;
PMID: 39701300
Background & Aims: Data on the effectiveness of classical non-selective beta-blockers (cNSBBs, i.e., propranolol and nadolol) vs. carvedilol in patients with cirrhosis are scarce. In the present study, we aimed...
6.
Abad J, Llop E, Arias-Loste M, Burgos-Santamaria D, Martinez Porras J, Iruzubieta P, et al.
Clin Gastroenterol Hepatol
. 2024 Dec;
PMID: 39694202
Metabolic dysfunction-associated steatohepatitis(MASH) is commonly seen in biopsy proven steatotic liver disease(SLD). Life-style intervention reaching a weight loss higher than 10% promotes MASH resolution, but this goal is only achieved...
7.
Llaneras J, Lens S, Valle B, Fernandez I, Macias J, Dominguez-Hernandez R, et al.
Emergencias
. 2024 Oct;
36(5):375-384.
PMID: 39364991
The prevalence of active hepatitis C virus (HCV) infection is higher in hospital emergency departments (EDs) than in the general population. Numerous patients who seek emergency care are unaware that...
8.
Feng G, Mozes F, Ji D, Treeprasertsuk S, Okanoue T, Shima T, et al.
Clin Gastroenterol Hepatol
. 2024 Oct;
PMID: 39362618
Background & Aims: Metabolic dysfunction-associated steatohepatitis (MASH) and fibrotic MASH are significant health challenges. This multi-national study aimed to validate the acMASH index (including serum creatinine and aspartate aminotransferase concentrations)...
9.
El Hajra I, Llop E, Blanco S, Perello C, Fernandez-Carrillo C, Calleja J
J Clin Med
. 2024 Sep;
13(18).
PMID: 39337086
Multiple studies have linked COVID-19 to a higher incidence of thromboembolic disorders. However, the association of COVID-19 with other potentially life-threatening complications, such as splanchnic vein thrombosis, is less well...
10.
Noureddin M, Truong E, Mayo R, Martinez-Arranz I, Minchole I, Banales J, et al.
Hepatology
. 2024 Sep;
81(1):E12-E16.
PMID: 39325967
No abstract available.